Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer

Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid receptor (GR) is upregulated in this context, stimu...

Full description

Bibliographic Details
Main Authors: Jianneng Li, Mohammad Alyamani, Ao Zhang, Kai-Hsiung Chang, Michael Berk, Zhenfei Li, Ziqi Zhu, Marianne Petro, Cristina Magi-Galluzzi, Mary-Ellen Taplin, Jorge A Garcia, Kevin Courtney, Eric A Klein, Nima Sharifi
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2017-02-01
Series:eLife
Subjects:
prostate cancer
androgens
glucocorticoids
nuclear receptors
treatment resistance
Online Access:https://elifesciences.org/articles/20183

Internet

https://elifesciences.org/articles/20183

Similar Items